Preparation and immunological evaluation of inactivated avian influenza virus vaccine encapsulated in chitosan nanoparticles

Mohamed, Samah H.; Arafa, Abdel Satar; Mady, Wesam; Fahmy, Hanan A.; Omer, Lamiaa M.; Morsi, Rania E.

doi:10.1016/j.biologicals.2017.10.004

Cited by 29 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In endemic regions, besides biosecurity, the specific immunoprophylaxis measures remain the most important means of disease prevention and control. Several approaches have been attempted so far, including the use of pbENPs for enhancing the mucosal immune response along the respiratory tract [93,[95][96][97].…”

Section: Influenza Antigens Encapsulated In Plga Npsmentioning

confidence: 99%

Fate of Biodegradable Engineered Nanoparticles Used in Veterinary Medicine as Delivery Systems from a One Health Perspective

et al. 2021

View full text Add to dashboard Cite

The field of veterinary medicine needs new solutions to address the current challenges of antibiotic resistance and the need for increased animal production. In response, a multitude of delivery systems have been developed in the last 20 years in the form of engineered nanoparticles (ENPs), a subclass of which are polymeric, biodegradable ENPs, that are biocompatible and biodegradable (pbENPs). These platforms have been developed to deliver cargo, such as antibiotics, vaccines, and hormones, and in general, have been shown to be beneficial in many regards, particularly when comparing the efficacy of the delivered drugs to that of the conventional drug applications. However, the fate of pbENPs developed for veterinary applications is poorly understood. pbENPs undergo biotransformation as they are transferred from one ecosystem to another, and these transformations greatly affect their impact on health and the environment. This review addresses nanoparticle fate and impact on animals, the environment, and humans from a One Health perspective.

show abstract

Section: Influenza Antigens Encapsulated In Plga Npsmentioning

confidence: 99%

Fate of Biodegradable Engineered Nanoparticles Used in Veterinary Medicine as Delivery Systems from a One Health Perspective

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Chitosanbased nanoparticles have been widely used in vaccine development-examples include vaccines against Clostridium botulinum type A neurotoxins, Neospora, hepatitis B virus, and Newcastle disease [16]. Chickens inoculated with inactivated avian influenza virus (AIV)-chitosan-nanoparticles showed the highest haemagglutination inhibition (HI) antibody titer weeks after the inoculation phagocytic activity, and phagocytic index in the AIV-chitosan nanoparticles group significantly increased [61]. To prevent bronchitis caused by respiratory syncytial virus (RSV), chitosan-DNA nanospheres administered intranasally induced the expression of corresponding protein, and improved the levels of anti-RSVspecific IgG, sIgA, cytotoxic T lymphocytes, and IFN- [62].…”

Section: Chitosan-based Nanoparticlesmentioning

confidence: 99%

Applications of polymer-based nanoparticles in vaccine field

Guo

Utupova

et al. 2019

Nanotechnology Reviews

View full text Add to dashboard Cite

Polymer-based nanoparticles have good solubility, stability, safety, and sustained release,which increases the absorption of loaded drugs, protects the drugs from degradation, and prolongs their circulation time and targeted delivery. Generally, we believe that prevention and control of infectious diseases through inoculation is the most efficient measure. However, these vaccines including live attenuated vaccines, inactivated vaccines, protein subunit vaccines, recombinant subunit vaccines, synthetic peptide vaccines and DNA vaccines have several defects, such as immune tolerance, poor immunogenicity, low expression level and induction of respiration pathological changes. All kinds of biodegradable natural and synthetic polymers play major roles in the vaccine delivery system to control the release of antigens for an extended period of time. In addition, these polymers also serve as adjuvants to enhance the immunogenicity of vaccine. This review mainly introduces natural and synthetic polymer-based nanoparticles and their formulation and properties. Moreover, polymer-based nanoparticles as adjuvants and delivery carriers in the applications of vaccine are also discussed. This review provides the basis for further operation of nano vaccines by utilizing the polymer-based nanoparticles as vaccine adjuvants and delivery systems. Polymer-based nanoparticles have exhibited great potential in improving the immunogenicity of antigens and the development of nano vaccines in future.

show abstract

“…Recent studies in pigs and chickens have shown an increase in the immunogenicity of inactivated influenza vaccines encapsulated in PLGA NPs or chitosan NPs [ 11 , 43 , 53 ]. In the present study, we showed that inactivated AIV and CpG ODN encapsulated in PLGA NPs induced higher lachrymal IgG and serum antibody (IgG, IgM and HI) upon subcutaneous delivery.…”

Section: Discussionmentioning

confidence: 99%

Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens

et al. 2018

View full text Add to dashboard Cite

Mucosal vaccine delivery systems have paramount importance for the induction of mucosal antibody responses. Two studies were conducted to evaluate immunogenicity of inactivated AIV antigens encapsulated in poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs). In the first study, seven groups of specific pathogen free (SPF) layer-type chickens were immunized subcutaneously at 7-days of age with different vaccine formulations followed by booster vaccinations two weeks later. Immune responses were profiled by measuring antibody (Ab) responses in sera and lachrymal secretions of vaccinated chickens. The results indicated that inactivated AIV and CpG ODN co-encapsulated in PLGA NPs (2x NanoAI+CpG) produced higher amounts of hemagglutination inhibiting antibodies compared to a group vaccinated with non-adjuvanted AIV encapsulated in PLGA NPs (NanoAI). The tested adjuvanted NPs-based vaccine (2x NanoAI+CpG) resulted in higher IgG responses in the sera and lachrymal secretions at weeks 3, 4 and 5 post-vaccination when immunized subcutaneously. The incorporation of CpG ODN led to an increase in Ab-mediated responses and was found useful to be included both in the prime and booster vaccinations. In the second study, the ability of chitosan and mannan coated PLGA NPs that encapsulated AIV and CpG ODN was evaluated for inducing antibody responses when delivered via nasal and ocular routes in one-week-old SPF layer-type chickens. These PLGA NPs-based and surface modified formulations induced robust AIV-specific antibody responses in sera and lachrymal secretions. Chitosan coated PLGA NPs resulted in the production of large quantities of lachrymal IgA and IgG compared to mannan coated NPs, which also induced detectable amounts of IgA in addition to the induction of IgG in lachrymal secretions. In both mucosal and subcutaneous vaccination approaches, although NPs delivery enhanced Ab-mediated immunity, one booster vaccination was required to generate significant amount of Abs. These results highlight the potential of NPs-based AIV antigens for promoting the induction of both systemic and mucosal immune responses against respiratory pathogens.

show abstract

Preparation and immunological evaluation of inactivated avian influenza virus vaccine encapsulated in chitosan nanoparticles

Cited by 29 publications

References 39 publications

Fate of Biodegradable Engineered Nanoparticles Used in Veterinary Medicine as Delivery Systems from a One Health Perspective

Fate of Biodegradable Engineered Nanoparticles Used in Veterinary Medicine as Delivery Systems from a One Health Perspective

Applications of polymer-based nanoparticles in vaccine field

Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens

Contact Info

Product

Resources

About